

# James D Brenton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5142681/publications.pdf>

Version: 2024-02-01

180  
papers

26,735  
citations

17429

63  
h-index

6643

156  
g-index

200  
all docs

200  
docs citations

200  
times ranked

37638  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies. <i>International Journal of Gynecological Pathology</i> , 2022, 41, 12-19.	0.9	10
2	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 132-141.	1.1	12
3	High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 443-452.	1.1	2
4	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
5	Refined characterization of circulating tumor DNA through biological feature integration. <i>Scientific Reports</i> , 2022, 12, 1928.	1.6	18
6	Validated biomarker assays confirm that <i>ARID1A</i> loss is confounded with <i>MMR</i> deficiency, <i>CD8</i> <sup>+</sup> <i>TIL</i> infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. <i>Journal of Pathology</i> , 2022, 256, 388-401.	2.1	15
7	The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2911-2922.	3.2	19
8	Magnetization transfer imaging of ovarian cancer: initial experiences of correlation with tissue cellularity and changes following neoadjuvant chemotherapy. <i>BJR   Open</i> , 2022, 4, .	0.4	0
9	Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	6
10	A pan-cancer compendium of chromosomal instability. <i>Nature</i> , 2022, 606, 976-983.	13.7	111
11	Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis. <i>European Journal of Cancer</i> , 2022, 171, 85-95.	1.3	8
12	Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. <i>Clinical Cancer Research</i> , 2022, 28, 4947-4956.	3.2	22
13	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 217-228.	1.1	12
14	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021, 34, 194-206.	2.9	21
15	Ultrasound-guided targeted biopsies of CT-based radiomic tumour habitats: technical development and initial experience in metastatic ovarian cancer. <i>European Radiology</i> , 2021, 31, 3765-3772.	2.3	20
16	Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis. <i>British Journal of Cancer</i> , 2021, 124, 1130-1137.	2.9	11
17	FrenchFISH: Poisson Models for Quantifying DNA Copy Number From Fluorescence In Situ Hybridization of Tissue Sections. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 176-186.	1.0	2
18	Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?. <i>Seminars in Cancer Biology</i> , 2021, 77, 67-82.	4.3	12

#	ARTICLE	IF	CITATIONS
19	Promises and challenges of adoptive T-cell therapies for solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 1759-1776.	2.9	113
20	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2021, 161, 668-675.	0.6	7
21	TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer. <i>Cancer Research</i> , 2021, 81, 5706-5719.	0.4	64
22	p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. <i>Journal of Pathology</i> , 2020, 250, 336-345.	2.1	164
23	Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma. <i>Cancers</i> , 2020, 12, 3403.	1.7	24
24	Genomic landscape of platinum resistant and sensitive testicular cancers. <i>Nature Communications</i> , 2020, 11, 2189.	5.8	43
25	Unraveling tumor immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. <i>Nature Genetics</i> , 2020, 52, 582-593.	9.4	136
26	Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma. <i>Human Pathology</i> , 2020, 101, 40-52.	1.1	4
27	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	3.2	43
28	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. <i>British Journal of Cancer</i> , 2020, 123, 793-802.	2.9	35
29	Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene. <i>PLoS ONE</i> , 2020, 15, e0235766.	1.1	2
30	PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. <i>Cells</i> , 2020, 9, 442.	1.8	7
31	Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1803-1810.	2.9	23
32	Detection of ctDNA from Dried Blood Spots after DNA Size Selection. <i>Clinical Chemistry</i> , 2020, 66, 697-705.	1.5	34
33	Tissue-specific and interpretable sub-segmentation of whole tumour burden on CT images by unsupervised fuzzy clustering. <i>Computers in Biology and Medicine</i> , 2020, 120, 103751.	3.9	27
34	Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer. <i>Insights Into Imaging</i> , 2020, 11, 94.	1.6	30
35	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2019, 79, 505-517.	0.4	49
36	Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer. <i>Scientific Reports</i> , 2019, 9, 10742.	1.6	10

#	ARTICLE	IF	CITATIONS
37	Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. <i>Radiology</i> , 2019, 293, 374-383.	3.6	25
38	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
39	Sodium MRI with 3D-cones as a measure of tumour cellularity in high grade serous ovarian cancer. <i>European Journal of Radiology Open</i> , 2019, 6, 156-162.	0.7	12
40	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. <i>Modern Pathology</i> , 2019, 32, 1834-1846.	2.9	54
41	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. <i>Cancer Medicine</i> , 2019, 8, 2503-2513.	1.3	6
42	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , 2019, 125, 1963-1972.	2.0	39
43	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GClG phase 3 randomised controlled trial. <i>Lancet, The</i> , 2019, 394, 2084-2095.	6.3	142
44	Genomic Applications in Ovarian Cancer. , 2019, , 471-482.		0
45	<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 210-219.	7.7	278
46	A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5518-5518.	0.8	15
47	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	1.4	22
48	Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. <i>Cancer Discovery</i> , 2018, 8, 304-319.	7.7	255
49	Enhanced detection of circulating tumor DNA by fragment size analysis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	670
50	Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. <i>ESMO Open</i> , 2018, 3, e000408.	2.0	4
51	Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 883-892.	1.2	81
52	Personalising Treatment for High-Grade Serous Ovarian Carcinoma. <i>Clinical Oncology</i> , 2018, 30, 515-524.	0.6	16
53	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 250-261.	1.3	70
54	You won't believe this old test that does cheap single-cell mutation detection. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 149-153.	1.3	14

#	ARTICLE	IF	CITATIONS
55	Copy number signatures and mutational processes in ovarian carcinoma. <i>Nature Genetics</i> , 2018, 50, 1262-1270.	9.4	320
56	Liquid biopsies come of age: towards implementation of circulating tumour DNA. <i>Nature Reviews Cancer</i> , 2017, 17, 223-238.	12.8	1,786
57	CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours. <i>Nature Communications</i> , 2017, 8, 14432.	5.8	379
58	Development of Cell-Permeable, Non-Helical Constrained Peptides to Target a Key Protein-Protein Interaction in Ovarian Cancer. <i>Angewandte Chemie</i> , 2017, 129, 539-544.	1.6	6
59	Development of Cell-Permeable, Non-Helical Constrained Peptides to Target a Key Protein-Protein Interaction in Ovarian Cancer. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 524-529.	7.2	41
60	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 75-87.	5.1	975
61	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
62	Dose-Response Association of CD8 <sup>+</sup> Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	3.4	260
63	Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2017, 147, 267-275.	0.6	222
64	Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. <i>BMC Cancer</i> , 2017, 17, 657.	1.1	48
65	Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5608-TPS5608.	0.8	2
66	Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. <i>Oncotarget</i> , 2017, 8, 50930-50940.	0.8	43
67	SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells. <i>PLoS ONE</i> , 2016, 11, e0162698.	1.1	25
68	Intensive cisplatin/oral etoposide for epithelial ovarian cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 239-244.	0.7	2
69	Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5095-5101.	2.9	49
70	Structural and calorimetric studies demonstrate that the hepatocyte nuclear factor 1 $\beta$ (HNF1 $\beta$ ) transcription factor is imported into the nucleus via a monopartite NLS sequence. <i>Journal of Structural Biology</i> , 2016, 195, 273-281.	1.3	4
71	Sequencing Structural Variants in Cancer for Precision Therapeutics. <i>Trends in Genetics</i> , 2016, 32, 530-542.	2.9	86
72	Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 247-258.	1.3	280

#	ARTICLE	IF	CITATIONS
73	New paradigms for <i>BRCA1</i> / <i>BRCA2</i> testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. <i>Journal of Medical Genetics</i> , 2016, 53, 655-661.	1.5	57
74	Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 21.	2.2	66
75	Models of endometriosis and their utility in studying progression to ovarian clear cell carcinoma. <i>Journal of Pathology</i> , 2016, 238, 185-196.	2.1	38
76	Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5540-5540.	0.8	25
77	Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5549-5549.	0.8	11
78	PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5571-5571.	0.8	14
79	Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. <i>PLoS Medicine</i> , 2016, 13, e1002198.	3.9	219
80	Abstract A11: NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib.. , 2016, , .		0
81	CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11530-11530.	0.8	0
82	Circulating tumour DNA carrying patient-specific mutations in <i>TP53</i> as an early response biomarker in relapsed high grade serous ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23040-e23040.	0.8	1
83	Abstract 278: No cell left behind: Residual ovarian spheroids drive recurrence and are sensitive to the pro-oxidant elesclomol. , 2016, , .		1
84	Germline Mutation in <i>BRCA1</i> or <i>BRCA2</i> and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 652-657.	3.2	138
85	A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. <i>Molecular Oncology</i> , 2015, 9, 115-127.	2.1	38
86	Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis. <i>PLoS Medicine</i> , 2015, 12, e1001789.	3.9	314
87	Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. <i>Molecular Oncology</i> , 2015, 9, 791-805.	2.1	27
88	Molecular pathogenesis of ovarian clear cell carcinoma. <i>Future Oncology</i> , 2015, 11, 1389-1405.	1.1	26
89	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	12.8	839
90	A Bayesian adaptive design for biomarker trials with linked treatments. <i>British Journal of Cancer</i> , 2015, 113, 699-705.	2.9	26

#	ARTICLE	IF	CITATIONS
91	Genomic Applications in Epithelial Ovarian Malignancies. , 2015, , 489-502.		0
92	Abstract 2412: Assessment of clinical applications of circulating tumor DNA using an enhanced TAm-Seq platform. , 2015, , .		1
93	Abstract CT204: Preliminary results from PiSARRO, a phase Ib/II study of APR-246, a mutant p53 reactivating small molecule, in combination with standard chemotherapy in platinum-sensitive ovarian cancer. , 2015, , .		1
94	Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes. PLoS ONE, 2014, 9, e103988.	1.1	319
95	Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biology, 2014, 15, 526.	3.8	93
96	Phylogenetic Quantification of Intra-tumour Heterogeneity. PLoS Computational Biology, 2014, 10, e1003535.	1.5	126
97	Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists. BMC Cancer, 2014, 14, 891.	1.1	64
98	Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test-Retest Measurements for Tumor FDG Uptake, Diameter, and Volume. Clinical Cancer Research, 2014, 20, 2751-2760.	3.2	38
99	Abstract 1535: Immunohistochemistry predicts presence and type of TP53 mutation in high-grade serous carcinoma. Cancer Research, 2014, 74, 1535-1535.	0.4	2
100	Conditions Associated with Circulating Tumor-Associated Folate Receptor 1 Protein in Healthy Men and Women. PLoS ONE, 2014, 9, e96542.	1.1	23
101	Abstract CT339: Prospective molecular identification of ovarian cancer patients benefiting from PARP inhibitor (PARPi, rucaparib) maintenance therapy - reaching beyond germline BRCA mutations. , 2014, , .		0
102	A metadata-aware application for remote scoring and exchange of tissue microarray images. BMC Bioinformatics, 2013, 14, 147.	1.2	1
103	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncology, The, 2013, 14, 853-862.	5.1	335
104	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	9.4	326
105	Anatomy of an ovarian cancer. Nature, 2013, 495, 183-184.	13.7	8
106	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature, 2013, 497, 108-112.	13.7	1,443
107	The Xenopus Tgfbi is required for embryogenesis through regulation of canonical Wnt signalling. Developmental Biology, 2013, 379, 16-27.	0.9	7
108	Abstract IA19: Intratumoral heterogeneity and drug response in high-grade serous carcinoma. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
109	Abstract A27: The ovarian tumor tissue analysis (OTTA) consortium. <i>Clinical Cancer Research</i> , 2013, 19, A27-A27.	3.2	1
110	Advanced Ovarian Cancer: Multiparametric MR Imaging Demonstrates Response- and Metastasis-specific Effects. <i>Radiology</i> , 2012, 263, 149-159.	3.6	89
111	A-Ring Dihalogenation Increases the Cellular Activity of Combretastatin-Templated Tetrazoles. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 177-181.	1.3	42
112	Complex Stiffness Gradient Substrates for Studying Mechanotactic Cell Migration. <i>Advanced Materials</i> , 2012, 24, 6059-6064.	11.1	101
113	Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes. <i>BMC Genomics</i> , 2012, 13, 719.	1.2	32
114	$\beta$ 3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells. <i>Molecular Cancer</i> , 2012, 11, 36.	7.9	51
115	The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer. <i>Journal of Pathology</i> , 2012, 226, 703-712.	2.1	56
116	The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. <i>Nature</i> , 2012, 486, 346-352.	13.7	4,708
117	Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. <i>Journal of Pathology</i> , 2012, 227, 446-455.	2.1	81
118	Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA. <i>Science Translational Medicine</i> , 2012, 4, 136ra68.	5.8	1,086
119	Increased endothelial cell selectivity of triazole-bridged dihalogenated A-ring analogues of combretastatin 1. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 1749-1759.	1.4	18
120	Evolution of platinum resistance in high-grade serous ovarian cancer. <i>Lancet Oncology</i> , The, 2011, 12, 1169-1174.	5.1	165
121	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011, 11, 719-725.	12.8	1,084
122	Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer. <i>British Journal of Cancer</i> , 2011, 104, 361-368.	2.9	69
123	Total syntheses of subreamollines A and B. <i>Organic and Biomolecular Chemistry</i> , 2011, 9, 62-65.	1.5	32
124	Ovarian clear cell carcinoma—bad endometriosis or bad endometrium?. <i>Journal of Pathology</i> , 2011, 225, 157-160.	2.1	30
125	Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. <i>Gut</i> , 2011, 60, 499-508.	6.1	131
126	Two Novel Determinants of Etoposide Resistance in Small Cell Lung Cancer. <i>Cancer Research</i> , 2011, 71, 4877-4887.	0.4	35



#	ARTICLE	IF	CITATIONS
127	New Insights into Tubulin Binders. , 2011, , 259-278.		1
128	PathGrid: a service-orientated architecture for microscopy image analysis. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2010, 368, 3937-3952.	1.6	5
129	Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla. European Radiology, 2010, 20, 491-496.	2.3	59
130	Dynamic contrast-enhanced MRI in ovarian cancer: Initial experience at 3 tesla in primary and metastatic disease. Magnetic Resonance in Medicine, 2010, 63, 1044-1049.	1.9	44
131	Total syntheses of the bromotyrosine-derived natural products ianthelline, 5-bromoverongamine and JBIR-44. Tetrahedron Letters, 2010, 51, 4812-4814.	0.7	16
132	Driver mutations in <i>TP53</i> are ubiquitous in high grade serous carcinoma of the ovary. Journal of Pathology, 2010, 221, 49-56.	2.1	617
133	Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene, 2010, 29, 4905-4913.	2.6	153
134	Bcl-2 and $\beta$ 1-integrin predict survival in a tissue microarray of small cell lung cancer. British Journal of Cancer, 2010, 103, 1710-1715.	2.9	39
135	Slingshot: a PiggyBac based transposon system for tamoxifen-inducible "self-inactivating" insertional mutagenesis. Nucleic Acids Research, 2010, 38, e173-e173.	6.5	11
136	Tissue Banking of Diagnostic Lung Cancer Biopsies for Extraction of High Quality RNA. Journal of Thoracic Oncology, 2010, 5, 956-963.	0.5	26
137	S94 Two novel determinants of etoposide resistance in small cell lung cancer. Thorax, 2010, 65, A43-A44.	2.7	0
138	Evaluation of Nonenhancing Tumor Fraction Assessed by Dynamic Contrast-Enhanced MRI Subtraction as a Predictor of Decrease in Tumor Volume in Response to Chemoradiotherapy in Advanced Cervical Cancer. American Journal of Roentgenology, 2010, 195, 524-527.	1.0	33
139	Antivascular and anticancer activity of dihalogenated A-ring analogues of combretastatin A-4. MedChemComm, 2010, 1, 202.	3.5	23
140	The Specificity of the FOXL2 c.402C>G Somatic Mutation: A Survey of Solid Tumors. PLoS ONE, 2009, 4, e7988.	1.1	82
141	One-stop diagnostic breast clinics: how often are breast cancers missed?. British Journal of Cancer, 2009, 100, 1873-1878.	2.9	33
142	Chromosomal instability determines taxane response. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8671-8676.	3.3	244
143	The pitfalls of platform comparison: DNA copy number array technologies assessed. BMC Genomics, 2009, 10, 588.	1.2	80
144	Metabolic characterization of primary and metastatic ovarian cancer by <sup>1</sup> H-MRS in vivo at 3T. Magnetic Resonance in Medicine, 2009, 62, 855-861.	1.9	33

#	ARTICLE	IF	CITATIONS
145	A metadata approach for clinical data management in translational genomics studies in breast cancer. <i>BMC Medical Genomics</i> , 2009, 2, 66.	0.7	26
146	Semiquantitative and Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging Measurements Predict Radiation Response in Cervix Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 766-773.	0.4	140
147	Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique?. <i>European Radiology</i> , 2009, 19, 230-235.	2.3	48
148	Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary. <i>New England Journal of Medicine</i> , 2009, 360, 2719-2729.	13.9	706
149	Metadata-driven software for clinical trials. , 2009, , .		11
150	Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. <i>Breast Cancer Research</i> , 2008, 10, 214.	2.2	20
151	Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. <i>Human Molecular Genetics</i> , 2008, 17, 2633-2643.	1.4	124
152	<i>BEX2</i> Is Overexpressed in a Subset of Primary Breast Cancers and Mediates Nerve Growth Factor/Nuclear Factor- $\kappa$ B Inhibition of Apoptosis in Breast Cancer Cell Lines. <i>Cancer Research</i> , 2007, 67, 6725-6736.	0.4	81
153	High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. <i>Genome Biology</i> , 2007, 8, R215.	13.9	275
154	Genomic analysis of the 8p11-12 amplicon in familial breast cancer. <i>International Journal of Cancer</i> , 2007, 120, 714-717.	2.3	30
155	A gene-expression signature to predict survival in breast cancer across independent data sets. <i>Oncogene</i> , 2007, 26, 1507-1516.	2.6	225
156	Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. <i>Oncogene</i> , 2007, 26, 1959-1970.	2.6	97
157	High resolution melting for mutation scanning of TP53 exons 5-8. <i>BMC Cancer</i> , 2007, 7, 168.	1.1	119
158	Regulators of Mitotic Arrest and Ceramide Metabolism Are Determinants of Sensitivity to Paclitaxel and Other Chemotherapeutic Drugs. <i>Cancer Cell</i> , 2007, 11, 498-512.	7.7	351
159	The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel. <i>Cancer Cell</i> , 2007, 12, 514-527.	7.7	202
160	A consensus prognostic gene expression classifier for ER positive breast cancer. <i>Genome Biology</i> , 2006, 7, R101.	13.9	82
161	MMASS: an optimized array-based method for assessing CpG island methylation. <i>Nucleic Acids Research</i> , 2006, 34, e136-e136.	6.5	44
162	Differential expression of selected histone modifier genes in human solid cancers. <i>BMC Genomics</i> , 2006, 7, 90.	1.2	209

#	ARTICLE	IF	CITATIONS
163	Metabolic Consequences of p300 Gene Deletion in Human Colon Cancer Cells. <i>Cancer Research</i> , 2006, 66, 7606-7614.	0.4	27
164	Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition. <i>British Journal of Cancer</i> , 2006, 94, 1326-1332.	2.9	41
165	Optimal Amounts of Fluorescent Dye Improve Expression Microarray Results in Tumor Specimens. <i>Molecular Biotechnology</i> , 2005, 30, 151-154.	1.3	4
166	Sizing up miRNAs as cancer genes. <i>Nature Medicine</i> , 2005, 11, 712-714.	15.2	189
167	The External RNA Controls Consortium: a progress report. <i>Nature Methods</i> , 2005, 2, 731-734.	9.0	328
168	A 1â€‰Mb minimal amplicon at 8p11â€‰12 in breast cancer identifies new candidate oncogenes. <i>Oncogene</i> , 2005, 24, 5235-5245.	2.6	146
169	Proposed methods for testing and selecting the ERCC external RNA controls. <i>BMC Genomics</i> , 2005, 6, 150.	1.2	130
170	A variational Bayesian mixture modelling framework for cluster analysis of gene-expression data. <i>Bioinformatics</i> , 2005, 21, 3025-3033.	1.8	73
171	Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?. <i>Journal of Clinical Oncology</i> , 2005, 23, 7350-7360.	0.8	798
172	Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt. <i>Breast Cancer Research</i> , 2005, 7, 96-9.	2.2	28
173	Microarray segmentation methods significantly influence data precision. <i>Nucleic Acids Research</i> , 2004, 32, e50-e50.	6.5	57
174	Expression microarray reproducibility is improved by optimising purification steps in RNA amplification and labelling. <i>BMC Genomics</i> , 2004, 5, 9.	1.2	45
175	Predictive cancer genomicsâ€”what do we need?. <i>Lancet, The</i> , 2003, 362, 340-341.	6.3	17
176	Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. <i>Cancer Research</i> , 2002, 62, 3466-76.	0.4	96
177	Molecular profiling of breast cancer: portraits but not physiognomy. <i>Breast Cancer Research</i> , 2001, 3, 77.	2.2	32
178	Imprinting and Gene Silencing in Mice and <i>Drosophila</i> . <i>Novartis Foundation Symposium</i> , 1998, 214, 233-250.	1.2	4
179	An imprinting element from the mouse H19 locus functions as a silencer in <i>Drosophila</i> . <i>Nature Genetics</i> , 1997, 16, 171-173.	9.4	105
180	Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12